2020
Cancer cure for 32 cancer types: results from the EUROCARE-5 study
Dal Maso L, Panato C, Tavilla A, Guzzinati S, Serraino D, Mallone S, Botta L, Boussari O, Capocaccia R, Colonna M, Crocetti E, Dumas A, Dyba T, Franceschi S, Gatta G, Gigli A, Giusti F, Jooste V, Minicozzi P, Neamtiu L, Romain G, Zorzi M, De Angelis R, Francisci S, Group T. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. International Journal Of Epidemiology 2020, 49: 1517-1525. PMID: 32984907, DOI: 10.1093/ije/dyaa128.Peer-Reviewed Original ResearchConceptsConditional relative survivalCancer patientsProstate cancerCancer cureChronic lymphocytic leukemia patientsProportion of patientsThyroid cancer patientsEUROCARE-5 studyLymphocytic leukemia patientsSame death ratePopulation-based indicatorsMelanoma patientsPatients' qualityCorpus uteriFatal casesLung cancerPancreatic cancerThyroid cancerLeukemia patientsBreast cancerGeneral populationRelative survivalPatientsSkin melanomaAge 55Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020, 136: 1134-1143. PMID: 32688395, PMCID: PMC7472711, DOI: 10.1182/blood.2020006965.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAnti-Inflammatory AgentsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsSARS-CoV-2Survival AnalysisTreatment OutcomeConceptsCOVID-19 diagnosisCLL patientsHigh riskCumulative Illness Rating Scale scoreCOVID-19Intensive care unit admissionOverall case fatality rateChronic lymphocytic leukemia patientsBruton tyrosine kinase inhibitorsMulticenter international experienceCare unit admissionSymptomatic COVID-19Severe acute respiratory syndrome coronavirus 2 infection riskCOVID-19 courseCase fatality rateRating Scale scoresFuture epidemiologic studiesLymphocytic leukemia patientsCoronavirus disease 2019Tyrosine kinase inhibitorsUnit admissionBaseline characteristicsMost patientsHospital admissionImmune dysfunction
2019
PS1132 INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Moore N, Aldubayan S, Taylor‐Weiner A, Stilgenbauer S, Getz G, Wu C, Van Allen E, Brown J. PS1132 INHERITED DNA REPAIR AND CELL CYCLE GENE DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere 2019, 3: 512-513. DOI: 10.1097/01.hs9.0000562812.55861.d4.Peer-Reviewed Original ResearchChronic lymphocytic leukemia patientsCell cycle genesChronic lymphocytic leukemiaDNA repairCycle genesVariant calling algorithmsCell cycle regulation pathwaysGenetically distinct cohortsLymphocytic leukemiaPathogenic ATM mutationQ-value <Calling algorithmsCHEK2 alterationsMutation enrichmentVariant enrichmentRisk genesPredisposition genesRegulation pathwaysMutation enrichment analysisCancer-free controlsEnrichment analysisATM mutationsGenesCase-control analysisCancer-free individualsInherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.
Moore N, Aldubayan S, Taylor-Weiner A, Stilgenbauer S, Getz G, Wu C, Van Allen E, Brown J. Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia. Journal Of Clinical Oncology 2019, 37: 1508-1508. DOI: 10.1200/jco.2019.37.15_suppl.1508.Peer-Reviewed Original ResearchCell cycle genesChronic lymphocytic leukemia patientsDNA repairChronic lymphocytic leukemiaCycle genesVariant calling algorithmsCell cycle regulation pathwaysGenetically distinct cohortsPathogenic ATM mutationQ-value <Lymphocytic leukemiaCalling algorithmsCHEK2 alterationsMutation enrichmentVariant enrichmentRisk genesPredisposition genesRegulation pathwaysMutation enrichment analysisEnrichment analysisATM mutationsCancer-free controlsGenesGenetic heritabilityCase-control analysis
2017
Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorDrug therapyCLL therapyChronic lymphocytic leukemia patientsElderly unfit patientsAdditional treatment optionsDuration of treatmentRepertoire of drugsImmune effector responsesLymphocytic leukemia patientsChronic lymphocytic leukemiaLong-term toxicityUnfit patientsPatient ageCD20 antibodyRisk stratificationCLL treatmentAsymptomatic individualsTherapy optionsTreatment optionsEffector responsesLeukemia patientsLymphocytic leukemiaCLL cellsTreatment approaches
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply